A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer

por Natalia J. Gurule, Caroline E. McCoach, Trista K. Hinz, Daniel T. Merrick, Adriaan Van Bokhoven, Jihye Kim, Tejas Patil, Jacob Calhoun, Raphael A. Nemenoff, Aik Choon Tan, Robert C. Doebele, Lynn E. Heasley
Publicado 2021